• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down0.32% Nasdaq Down0.62%

    Ironwood Pharmaceuticals, Inc. (IRWD)

    -NasdaqGS
    10.45 Down 0.38(3.51%) Apr 29, 4:00PM EDT
    |After Hours : 10.45 0.00 (0.00%) Apr 29, 4:55PM EDT
    ProfileGet Profile for:
    Ironwood Pharmaceuticals, Inc.
    301 Binney Street
    Cambridge, MA 02142
    United States - Map
    Phone: 617-621-7722
    Fax: 617-494-0480
    Website: http://www.ironwoodpharma.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Drugs - Generic
    Full Time Employees:474

    Business Summary 

    Ironwood Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, and commercialization of human therapeutic products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adult men and women suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Constella name in the European Union. It has collaboration agreements with Allergan plc and AstraZeneca AB to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other GI conditions in North America, as well as in China, Hong Kong, and Macau. Ironwood Pharmaceuticals, Inc. also has license agreement with Astellas Pharma Inc. to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other GI conditions in Europe, as well as Japan, South Korea, Taiwan, Thailand, the Philippines, and Indonesia; and Exact Sciences Corp. to co-promote Cologuard, a noninvasive stool DNA screening test for colorectal cancer. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was founded in 1998 and is headquartered in Cambridge, Massachusetts.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Ironwood Pharmaceuticals, Inc.

    Corporate Governance 
    Ironwood Pharmaceuticals, Inc.’s ISS Governance QuickScore as of Apr 1, 2016 is 7. The pillar scores are Audit: 2; Board: 8; Shareholder Rights: 8; Compensation: 5.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
     PayExercised
    Dr. Peter M. Hecht Ph.D. , 52
    Co-Founder, Chief Exec. Officer and Director
    107.00K9.51M
    Mr. Thomas Graney , 51
    Chief Financial Officer and Sr. VP of Fin. & Corp. Strategy
    764.00K0.00
    Dr. Mark G. Currie Ph.D., 61
    Chief Scientific Officer, Pres of R&D and Sr. VP
    702.00K375.00K
    Ms. Halley E. Gilbert Esq., 46
    Chief Legal Officer, Sr. VP and Sec.
    642.00K0.00
    Mr. Thomas A. McCourt , 59
    Chief Commercial Officer and Sr. VP of Marketing & Sales
    671.00K0.00
    Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders